BeyondSpring Announces Third Quarter 2021 Financial Results and Provides a Corporate Update


- Positive Phase 3 data in 2nd/3rd line NSCLC (Dublin-3): Superior efficacy benefit in plinabulin and docetaxel combination in overall survival, 2-year and 3-year OS rate, PFS, ORR, and significant reduction of grade 4 neutropenia vs. docetaxel alone

Read more here:
BeyondSpring Announces Third Quarter 2021 Financial Results and Provides a Corporate Update

Related Posts